MADIT-CRT Long-Term study of CRT defibrillators demonstrates reduction of risk in Mild Heart Failure patients- Boston Scientific

In the longest follow-up to date of cardiac resynchronization therapy (CRT) for Mild Heart Failure patients, Boston Scientific Corporation's exclusively sponsored and landmark Multicenter Automatic Defibrillator Implantation Trial � Cardiac Resynchronization Therapy (MADIT-CRT) study demonstrated significant and sustained survival benefit for the indicated population.

The long-term results, presented at the American College of Cardiology's 63rd Annual Scientific Session by Ilan Goldenberg, M.D., director of the department of cardiology at the Leviev Heart Center at Sheba Medical Center, Tel Hashomer, Israel, demonstrated a 41 percent relative reduction in the risk of death in patients with Mild Heart Failure and left bundle branch block who received a Boston Scientific defibrillator with CRT therapy, compared to patients who received a defibrillator alone. Over 80 percent of patients who received CRT therapy were still alive at seven years. In addition to the mortality benefit, the results demonstrate that these patients experienced a 62 percent relative reduction in the risk of experiencing a first heart failure event when compared to patients who did not receive CRT therapy.